~~<i id='5C13283B56'><strike id='5C13283B56'><tt id='5C13283B56'><pre id='5C13283B56'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：focus 2025-09-06 04:41:08 - browse：21

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Mass General Brigham physicians react to latest merger step

knowledge

hotspot

entertainment

hotspot

leisure time

Inanewstudyofmultiplesclerosis,patientsinoneparticularsubgrouphaddifferencesinnaturalkillercells,whi

WSS

What is microchimerism and how does it affect maternal health?

Life sciences investors close nearly $6 billion in new funds

After Sarepta trial failure, Duchenne families brace for more debate

Four alarming medical procedures we’re glad history forgot

Prime Medicine says its gene editing passes test in monkeys

Medicare must police algorithms in Medicare Advantage, Dems say

focus

fashion

knowledge

Cancer drug shortages should be causing more outrage

Lung cancer screening guidelines updated for cigarette smokers

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Pancreatic cancer is often deadly, but new discoveries are raising hope

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Explaining an after

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Kidney transplant patients stopped immunosuppressants in trial

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

hotspot

Researchers test human milk's ability to repair gut microbiome

Life sciences investors close nearly $6 billion in new funds

Prime Medicine says its gene editing passes test in monkeys

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Lung cancer screening guidelines updated for cigarette smokers

UnitedHealth, in a surprise, takes aim at Steward’s physician group

entertainment

hotspot

hotspot

leisure time